The article by Dierick (2025) highlights the growing interest in automated red blood cell exchange as a therapy for sickle cell disease (SCD). This interest is due to the limitations of current medication therapies and the fact that gene therapies, which could potentially cure SCD, are not yet widely accessible. The article emphasizes the need for a broader commitment to increase the availability of transfusion therapies to improve the quality of life for patients with SCD.
The article does not provide specific data or research methods but calls for action to expand access to these blood-based therapies. It suggests that while drug treatments are available, they are insufficient for many patients, and thus, alternative treatments like automated red blood cell exchange should be more readily available. This approach could offer significant benefits for those living with SCD until gene therapies become more accessible.
More Info 
Add to Calendar 